Stocks and Investing
Stocks and Investing
Wed, August 14, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Carter Gould Maintained (VOR) at Buy with Decreased Target to $3 on, Aug 14th, 2024
Published on 2024-10-28 13:39:00 - WOPRAI, Carter Gould
Carter Gould of Barclays, Maintained "Vor Biopharma Inc." (VOR) at Buy with Decreased Target from $10 to $3 on, Aug 14th, 2024.
Carter has made no other calls on VOR in the last 4 months.
There are 3 other peers that have a rating on VOR. Out of the 3 peers that are also analyzing VOR, 0 agree with Carter's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Carter
- Matthew Biegler of "Oppenheimer" Reiterated at Buy with Decreased Target to $10 on, Monday, May 13th, 2024
- Silvan Tuerkcan of "JMP Securities" Reiterated at Buy and Held Target at $12 on, Monday, May 13th, 2024
- David Nierengarten of "Wedbush" Reiterated at Buy and Held Target at $11 on, Friday, May 10th, 2024
Contributing Sources